Search
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Roflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigational[L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis. … The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023.
Categories: Agents to Treat Airway DiseaseGriseofulvin
go.drugbank.com/drugs/DB00400ApprovedVet approvedGriseofulvin may be given by mouth in the treatment of tinea infections.
Loxoprofen
go.drugbank.com/drugs/DB09212ApprovedInvestigationalIt is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. … Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigational[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. … [L7489] Atezolizumab was granted FDA approval on 18 October 2016.
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births
Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of … [L48066] In contrast to another RSV vaccine, [respiratory syncytial virus vaccine, adjuvanted] (Arexvy), Abrysvo is reconstituted with sterile water prior to injection and does not require the co-administration
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems. … It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease.
Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideRaltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalRaltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … [A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated.[A263211]